Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Passive immunization against hepatitis A.

J T Stapleton1

  • 1Department of Internal Medicine, Iowa City VA Medical Center, IA.

Vaccine
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Human serum immune globulin (Ig) effectively prevents hepatitis A virus (HAV) infection and disease. Low levels of HAV antibodies, even if undetectable by standard tests, are sufficient for protection, suggesting a method for evaluating vaccine efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating false positive HIV test results: a case report.

ASM case reports·2025
Same author

Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2023
Same author

Infection of Glia by Human Pegivirus Suppresses Peroxisomal and Antiviral Signaling Pathways.

Journal of virology·2021
Same author

Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients.

The Journal of infectious diseases·2012
Same author

GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection.

Journal of viral hepatitis·2010
Same author

Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy.

HIV clinical trials·2007

Area of Science:

  • Immunology
  • Virology
  • Public Health

Background:

  • Human serum immune globulin (Ig) administration is a proven method for preventing hepatitis A virus (HAV) infection.
  • Ig can reduce the severity of hepatitis A if given during the incubation period, potentially leading to subclinical infections or passive-active immunity.
  • The protective duration of Ig is dose-dependent, with high doses offering less than six months of protection.

Purpose of the Study:

  • To evaluate the efficacy of immune globulin in preventing hepatitis A.
  • To determine the antibody levels required for protection against HAV.
  • To establish a method for assessing the immunogenicity and efficacy of hepatitis A vaccines.

Main Methods:

  • Review of field studies on Ig administration for HAV prevention.

Related Experiment Videos

  • Detection of HAV antibodies in Ig preparations and recipients using commercial and sensitive immunoassays, as well as neutralization assays.
  • Correlation of antibody levels with protection efficacy.

    • Main Results:

    • Ig administration prevents HAV infection when given before exposure and reduces disease severity when given during incubation.
    • While standard immunoassays may not detect HAV antibodies in Ig recipients, more sensitive methods reveal low antibody titers.
    • Ig demonstrates approximately 90% efficacy in preventing hepatitis A, indicating that very low antibody levels are sufficient for protection.

    Conclusions:

    • Very low levels of hepatitis A virus antibodies are sufficient to prevent infection.
    • Measuring HAV antibodies elicited by vaccines using sensitive assays can predict vaccine immunogenicity and efficacy.
    • Immune globulin serves as a benchmark for understanding protective antibody levels against HAV.